Skip to main content

Advertisement

SpringerLink
Log in

Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias

  • Case Report
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

SOCS1 and SHP1 are negative regulators of the Jak/STAT signalling pathway that is implicated in leukaemogenesis. We studied if aberrant methylation of SOCS1 and SHP1 might be involved in the pathogenesis and prognostication of acute leukaemias by methylation-specific polymerase chain reaction (MSP). At diagnosis, methylation of SHP1 occurred more frequently in acute myeloid leukaemia (AML) (n=26, 52%) than acute lymphoblastic leukaemia (ALL) (n=6, 24%) (p=0.02). Methylation of SOCS1 was absent in both AML and ALL patients. SHP1 methylation was not associated with specific clinicopathologic features and had no prognostic impact on AML patients. Frequent methylation of SHP1, but not SOCS1, may be important in the pathogenesis, but not prognosis, of acute leukaemias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1A, B

Similar content being viewed by others

References

  1. Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95:19–29

    CAS  PubMed  Google Scholar 

  2. O’Shea JJ, Gadina M, Schreiber RD (2002) Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 [Suppl]:S121–S131

  3. Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410–416

    CAS  PubMed  Google Scholar 

  4. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, Salmeen A, Barford D, Tonks NK (2001) TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 276:47771

    Article  CAS  PubMed  Google Scholar 

  5. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921

    Article  CAS  PubMed  Google Scholar 

  6. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921–924

    CAS  PubMed  Google Scholar 

  7. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924–929

    Article  CAS  PubMed  Google Scholar 

  8. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 acute leukemias cells. Immunity 10:105–115

    CAS  PubMed  Google Scholar 

  9. Wu C, Sun M, Liu L, Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1-12

    Article  CAS  PubMed  Google Scholar 

  10. Chim CS, Liang R, Kwong YL (2002) Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol 20:167–176

    Article  CAS  PubMed  Google Scholar 

  11. Robertson KD, Wolffe AP (2000) DNA methylation in health and disease. Nat Rev 1:11–19

    Article  CAS  PubMed  Google Scholar 

  12. Singal R, Ginder GD (1999) DNA methylation. Blood 93:4059–4070

    CAS  PubMed  Google Scholar 

  13. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427–5440

    Article  CAS  PubMed  Google Scholar 

  14. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167

    Article  CAS  PubMed  Google Scholar 

  15. Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H (1999) A methylation suppresses transcription in vivo. Nat Genet 22:203–206

    PubMed  Google Scholar 

  16. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309–1312

    Article  CAS  PubMed  Google Scholar 

  17. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28:29–35

    Article  CAS  PubMed  Google Scholar 

  18. Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M, Kobayashi Y, Emi M (2003) Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 48:65–69

    CAS  PubMed  Google Scholar 

  19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458

    CAS  PubMed  Google Scholar 

  20. Second MIC Cooperative Study Group (1988) Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br J Haematol 68:487–494

    PubMed  Google Scholar 

  21. Chim CS, Liang R, Kwong YL, Lie AK, Todd D, Chan TK (1999) Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty-year experience (1975 to 1996). Aust N Z J Med 29:726–730

    CAS  PubMed  Google Scholar 

  22. Chim CS, Kwong YL, Chu YC, Chan CH, Chan YT, Liang R (1997) Improved treatment outcome in adult acute lymphoblastic leukemia using the intensive German protocol, a preliminary report. Hematol Oncol 15:19–26

    Article  CAS  PubMed  Google Scholar 

  23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826

    Article  CAS  PubMed  Google Scholar 

  24. Chim CS, Liang R, Tam C, Kwong YL (2001) P15 and P16 promoter methylation in acute promyelocytic leukemia. J Clin Oncol 19:2033–2040

    CAS  PubMed  Google Scholar 

  25. Chim CS, Tam C, Liang R, Kwong YL (2001) P15 and P16 gene methylation in adult acute leukemia: lack of prognostic significance. Cancer 91:2222–2229

    Article  CAS  PubMed  Google Scholar 

  26. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K, Akagi T (2002) Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62:6390–6394

    CAS  PubMed  Google Scholar 

  27. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA (1999) Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 18:375–385

    Article  CAS  PubMed  Google Scholar 

  28. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18:1309–1320

    Article  CAS  PubMed  Google Scholar 

  29. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P (2002) The tumor suppressor activity of SOCS-1. Oncogene 21:4351–4362

    Article  CAS  PubMed  Google Scholar 

  30. Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY, Yao M, Chen YC, Shen MC, Wang CH, Tien HF (2003) SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37:300-305

    Article  CAS  PubMed  Google Scholar 

  31. Melzner I, Möller P (2003) Silencing of the SOCS-1 gene by CpG methylation? Blood 102:1554–1555

    Article  CAS  PubMed  Google Scholar 

  32. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS (2003) Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 123:654–661

    Article  CAS  PubMed  Google Scholar 

  33. Melki JR, Vincent PC, Clark SJ (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730–3740

    PubMed  Google Scholar 

  34. Metcalf D, Alexander WS, Elefanty AG, Nicola NA, Hilton DJ, Starr R, Mifsud S, Di Rago L (1999) Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13:926–934

    Article  CAS  PubMed  Google Scholar 

  35. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS (1998) Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A 95:14395–14399

    Article  CAS  PubMed  Google Scholar 

  36. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247–254

    CAS  PubMed  Google Scholar 

  37. Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159:4720–4728

    CAS  PubMed  Google Scholar 

  38. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809–816

    CAS  PubMed  Google Scholar 

  39. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M (1998) Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 58:3173–3180

    CAS  PubMed  Google Scholar 

  40. Chim CS, Wong ASY, Kwong YL (2003) Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol 82:738–742

    Article  CAS  PubMed  Google Scholar 

  41. He J, Olson JJ, James CD (1995) Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833-4836

    CAS  PubMed  Google Scholar 

  42. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475–5483

    CAS  PubMed  Google Scholar 

  43. Drexler HG (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845–859

    Article  CAS  PubMed  Google Scholar 

  44. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55:6200–6209

    CAS  PubMed  Google Scholar 

  45. Schauer IE, Siriwardana S, Langan TA, Sclafani RA (1994) Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 91:7827–7831

    CAS  PubMed  Google Scholar 

  46. Wijermans P, Lubbert M, Verhoef G, et al. (2000) Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962

    PubMed  Google Scholar 

  47. Silverman LR, Demakos EP, Bercedis L, et al. (2002) A randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440

    CAS  PubMed  Google Scholar 

  48. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This study was supported by the Kadoorie Charitable Foundation. Pathologic diagnoses of he leukaemias were performed in the Department of Pathology, Queen Mary Hospital.

Author information

Authors and Affiliations

  1. University Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong

    C. S. Chim, A. S. Y. Wong & Y. L. Kwong

Authors
  1. C. S. Chim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. S. Y. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. L. Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. L. Kwong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chim, C.S., Wong, A.S.Y. & Kwong, Y.L. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol 83, 527–532 (2004). https://doi.org/10.1007/s00277-004-0843-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-004-0843-1

Keywords

Search

Navigation